Initial studies reported increased levels of serglycin only in hematological malignancies like multiple myeloma and leukemia; however, more recent findings suggest that serglycin is overexpressed in glioma and tumors of the breast, prostate, lung, and liver (123, 124, 125, 126, 127). Here, SRGN is linked to leukemia.